Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — H1 2020 Earnings Presentation
15 slides from Innate Pharma Sa Class A's earnings presentation, Sep 8, 2020
Slide 1: Half Year 2020 Results
HALF YEAR 2020 RESULTS SEPTEMBER 8, 2020
Slide 2: Forward Looking Statements
Forward Looking Statements This document has been prepared by Innate Pharma S.A. (the “Company”) solely for This presentation discusses product candidates that are under clinical development the purposes of a presentation to investors concerning the Company. This document and which have not yet been
Slide 3: Our Leadership Team
Our Leadership Team Today on the conference call Mondher Mahjoubi Laure-Hélène Mercier Chief Executive Officer EVP, Chief Financial Officer Chairman of the Executive Board Executive Board Member Joyson Karakunnel Jennifer Butler EVP, Chief Medical Officer EVP, U.S. General Manager 3
Slide 4: Our Strategy
Our Strategy We strive to achieve scientific leadership in immunotherapy by leveraging our expertise in innate immunity and transition to a commercial stage biotech Science Commercial Finance • Deliver the current • Build commercial • Continue to pipeline & prepare capabilities for strengthen financ
Slide 5: First Half 2020 Major Milestones
First Half 2020 Major Milestones Maintained momentum and business continuity despite COVID-19 pandemic Science Commercial Finance • Lacutamab: Resumed • Filing for marketing authorization • €184.6m as of June 30, 2020; enrollment of Phase 2 in Europe cash projected through 2022 TELLOMAK study in SS
Slide 6: Lacutamab: Lead Late-Stage Proprietary Asset
Lacutamab Lead Late-Stage Proprietary Asset Building rare hem-onc franchise TELLOMAK Phase 2 Study Cohort #1 – Sezary syndrome N=60 Cohort #2 – Mycosis fungoides N=90 ≥ 2 prior systemic therapies must include mogamulizumab ≥ 2 prior systemic therapies including biological agents Cohort #2: Cohort #3
Slide 7: Monalizumab: Lead Partnered Asset Advancing to Phase 3
Monalizumab Lead Partnered Asset Advancing to Phase 3 First program to advance into a Phase 3 study for patients with IO pre-treated SCCHN • 2H20: Phase 3 expected to start Phase 2 Expansion Cohort 2 o Monalizumab + cetuximab in IO-pretreated R/M Monalizumab + cetuximab, IO Pretreated R/M SCCHN** SC
Slide 8: Avdoralimab: Exploring Inflammation in COVID-19 and beyond
Avdoralimab Exploring Inflammation in COVID-19 and beyond COVID-19 severe pneumonia Other inflammatory diseases • FORCE Phase 2; enrollment ongoing • Targeting C5a/C5aR has been demonstrated • Published translational data in Nature supporting a scientifically and through positive clinical trials in
Slide 9: Lumoxiti: Establishing Commercial Footprint in Rare Hem-Oncology
Lumoxiti Establishing Commercial Footprint in Rare-Hem-Oncology Full Transition from AstraZeneca on-track by end of year Establish US Commercial Fully Independent, Drive Lumoxiti Sales Organization Building Franchise • Establish Innate as a • Recruited experienced US team • By end of the year, US co
Slide 10: Market Opportunity for Lumoxiti
Lumoxiti Market Opportunity for Lumoxiti 2020 sales impacted by COVID-19 Critical Success Market Opportunity COVID-19 Factors • 3L HCL patients; 380 patients in • Reaching beyond centers of • Impacted face-to-face US excellence (COEs) / academic interactions across the centers as patients are manage
Slide 11: First Half 2020 Financial Highlights
First Half 2020 Financial Highlights Cash, cash equivalents and financial assets: €184.6m as of June 30, 2020 • Sufficient to fund operations through 2022 Net income from Revenue/other income: Operating expenses: distribution agreements: €36.7m €46.0m €0.9m Licensing and collaborations: 69% expenses
Slide 12: First Half 2020 Financial Highlights
First Half 2020 Financial Highlights In thousands of euros, except for data per share June 30, 2020 December 31, 2019 Revenue and other income 36,745 59,155 Research and development (31,499) (36,584) Selling, general and administrative (14,490) (9 295) Total operating expenses (45,989) (45,879) Net
Slide 13: Summary
Summary Progress across our portfolio • Lacutamab TELLOMAK study resumed 1 • Monalizumab moving to Phase 3 • Exploring avdoralimab in inflammation Established US commercial infrastructure for Lumoxiti 2 • Creating foundation for future rare-oncology franchise Momentum to continue in 2H20 & 2021 3 •
Slide 14: Welcome Joyson, Innate's New Chief Medical Officer
Welcome Joyson, Innate’s New Chief Medical Officer • Experienced medical oncologist and hematologist • More than 15 years of drug development expertise both in academia and biopharmaceutical industry • Also serves a medical advisor to the Parker Institute for Cancer Immunotherapy 14
Slide 15: Anticipated Major Newsflow
Anticipated Major Newsflow Lumoxiti Lumoxiti Complete commercial Potential EU approval transition Monalizumab Monalizumab Preliminary data Ph 3 initiation + $50m milestone Expansion Cohort 3 SCCHN Monalizumab Updated data expansion Cohort 2 SCCHN Avdoralimab Lacutamab Lacutamab Initiate investigator